Full Year Results Release
Released
Released
Announcement PDF
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
25 February 2021
Imagion Biosystems 2020 Full-Year Results
2020 Highlights:
• MagSenseTM HER2 breast cancer Phase I study initiated
• Collaboration with Siemens Healthineers explores MagSenseTM nanoparticles using
MRI
• Total of A$12.2 million funds raised (after costs) in 2020 supporting continued
MagSenseTM HER2 Breast Cancer product development and expanding the product
pipeline
• Strong cash position at year end of A$13.2 million
MELBOURNE - Imagion Biosystems (ASX: IBX), a company dedicated to improving healthcare
through the early detection of cancer, today released its Appendix 4E and Annual Report for the
year ended 31 December 2020.
2020 Operational Execution
A key operational focus in 2020 was to progress development of the novel MagSenseTM
technology and initiate a first-in-human study for HER2 breast cancer. The Company reported a
Phase 1 study was opened for enrolment in December 2020 with the first clinical site being
announced as Monash Health in Melbourne, Australia. The study will be undertaken in
collaboration with multiple sites across Australia.
Key achievements in 2020 related to achieving commencement of the study have included:
• Manufacturing of the MagSenseTM nanoparticle formulation for use in the Phase I study;
• Establishing a collaboration with Siemens Healthineers to expand the scope of the study
to include Magnetic Resonance Imaging (MRI); and
• Obtaining Human Research Ethics Committee (HREC) approval for the MagSenseTM
HER2 Phase I study.
Improved Financial Position
Imagion’s cash balance stood at $13.2 million at end of 2020. Cash was boosted by several
capital raises during 2020 raising $12.2 million (net of costs). The Company also received $2.6
million from the exercise of options in 2020, this is expected to increase into 2021 as options
move closer to their expiry dates.
In April 2020 Imagion also received $2.2 million in Research & Development tax incentives from
the Australian Taxation Office in respect of its 2019 Research & Development costs. A
materially similar amount is expected in the second quarter of 2021 in respect of the 2020
Research & Development costs.
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
®
Operating cash outflows were up 11% to $4.6 million in 2020 reflecting slightly higher costs as
the Company progressed towards the Phase I study.
Overall, the Company’s net loss was $5.4 million. This represents a $2.0 million increase
compared to 2019 (loss of $3.4 million), however, over $1.3 million related to increased share
based payments (2019 included a material reversal of prior year expenses). The balance of $0.7
million representing an 11% increase in expenditure as the Company progressed towards the
Phase 1 Study.
Executive Chairman and CEO Bob Proulx said, “2020 has been a breakout year for Imagion.
After much diligence and hard work, we are delighted to have finished the year with our first inhuman study established and open for enrolment. We are excited for what lies ahead in 2021,
particularly as the MagSenseTM HER2 breast cancer Phase I study progresses and we explore
further development areas including manufacturing scale-up and preparing for a larger pivotal
study.”
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology the Company aims to detect cancer and other
diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed
on the Australian Securities Exchange (ASX) in June 2017.
Authorisation & Additional Information
This Announcement was authorised by the Board of Directors of Imagion Biosystems Limited
For further information please visit www.imagionbiosystems.com
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Australian Media & Investor Relations:
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
Share your feedback
Discover